Gilead

Yescarta is the first CAR T-Cell therapy approved for indolent follicular lymphoma

It is authorised or approved for use as a COVID-19 treatment in more than 50 countries

Veklury shortened time to recovery by five days in hospitalised COVID-19 patients

They assured that they will work towards developing innovations to fight the COVID-19 pandemic, ensuring their timely availability…

Gilead Japan will hold marketing authorisation of Jyseleca in Japan while Eisai will be responsible for product distribution

There is no shortage of candidates to help with COVID-19, but what is lacking right now is data on their efficacy

The pharmaceutical company’s move stirred the global debate about equitable access to drugs and brought concerns about…

Truvada generated $2.8 billion in sales last year, both from treatment and preventing an HIV infection

Four multinational clinical trials that are planning to enrol the most subjects are investigating remdesivir, sarilumab and…

Gilead’s three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola